Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Rhea-AI Summary

Altimmune (Nasdaq: ALT) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day, during which management will discuss financial results and provide a business update.

The conference call will be accessible through a webcast on Altimmune's Investor Relations website. Interested participants can register online to receive dial-in numbers and a unique PIN for call access. A replay of the call will be available on the company's Investor Relations website for up to three months following the event.

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.

Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

FAQ

When will Altimmune (ALT) report Q4 and full year 2024 earnings?

Altimmune will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.

What time is Altimmune's (ALT) Q4 2024 earnings call?

Altimmune's earnings conference call is scheduled for 8:30 am E.T. on February 27, 2025.

How can investors access Altimmune's (ALT) Q4 2024 earnings call?

Investors can access the call through a webcast on Altimmune's Investor Relations website or register online to receive dial-in numbers and a unique PIN.

How long will Altimmune's (ALT) Q4 2024 earnings call replay be available?

A replay of the earnings call will be available on Altimmune's Investor Relations website for up to three months after the call.